Search Results - lei+zheng

3 Results

Sort By:

Semaphorin 3D and Plexin D1 as New Therapeutic Targets for Pancreatic Cancer Treatment

Unmet Need: Most patients with pancreatic ductal adenocarcinoma (PDA) present with metastatic disease at the time of diagnosis or will recur with metastases after surgical treatment. Technology Overview: Semaphorin-plexin signaling mediates the migration of neuronal axons during development and of blood vessels during angiogenesis. The expression of...

Published: 6/26/2025 | Inventor(s): Lei Zheng

Keywords(s): Biomarker, Cancer Cells, Cancers, Cell Model, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Mechanism-of-action Biomarker, Pancreatic Cancer, Target, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

PD-1/PD-L1 Blockade together with Vaccine Therapy Facilitates Effector T Cell Infiltration into Pancreatic Tumors

Novel Combination Therapy for Pancreatic Cancer TreatmentJHU REF: C12915Invention Novelty: The technology is the novel combination of PD1/PD-L1 blockade antibody and vaccine-based immunotherapy to treat pancreatic cancer.Value Proposition:Pancreatic cancer is one of the top cancer killers in the United States due to late detection and resistance to...

Published: 6/26/2025 | Inventor(s): Elizabeth Jaffee, Lei Zheng

Keywords(s): Biologics, Cancers, Combination, Disease Indication, Pancreatic Cancer, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Annexin A2 is a Cancer Target Recognized by Antibodies and T Cells and is Involved in Cancer Development and Progression

C10569: Molecular Target to Diagnose & Treat Pancreatic Cancer & Methods to Identify New Targets Value Proposition: ADVANTAGES • Diagnostic and therapeutic target for pancreatic cancer • Molecular target to develop vaccines and antagonistic antibodies for therapy and prevention • Confirmed T cell response for robust, diverse,...

Published: 6/26/2025 | Inventor(s): Lanqing Huang, Lei Zheng, Elizabeth Jaffee

Keywords(s): Biomarker, Cancers, Disease Indication, Immunotherapy, Pancreatic Cancer, Pharmakodynamic Biomarker, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology